In an bid to tap a growing interest in using microRNAs as biomarkers of disease or tissue injury, Somagenics has developed a platform for detecting the small, non-coding RNAs in circulation.

Somagenics hopes the platform, called miR-Direct, will attract the attention of an industry partner interested in commercializing it. Meanwhile, the company is continuing to press ahead with its efforts in RNAi therapeutics with a focus on wound healing after pulling back on its hepatitis C program in the wake of advances made by other drugmakers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.